紫杉醇酯质体对比多西他赛联合顺铂治疗晚期非小细胞肺癌的护理体会

摘要

Objective To compare the effect of Paclitaxel Liposomal plus cisplatin(LP)and Docetaxel combined with Cisplatinum(DP)in the treatment of terminal non-small cell lung cancer (NSCLC).Methods A total of 60 patients were randomly divided into experimental group and control group with 30 patients in each group.Experimental group was treated with LP at a dose of 135 mg /m2 and the control group was given DP at a dose of 75 mg /m2,the cycle of two groups was 21 days.The curative effectiveness and adverse reaction were evaluated after 2 cycles.Results The difference was not significant in the clinical efficacy(P >0.05).The difference was statisti-cally significant since the incidence of peripheral neuritis in the experimental group was significantly lower than that in the control group(P <0.05).The difference was not statistically significant in nausea /vomiting,diarrhea,abdominal pain and alopecia (P >0.05).Conclusion The effects of LP and DP in the treatment of NSCLC are similar.However,LP treatment with better clinical ef-ficacy reduces the incidence rate of peripheral neuritis and decreases the occurrence of adverse reac-tion.%目的：对比紫杉醇酯质体联合顺铂（LP）与多西他赛联合顺铂（DP）治疗晚期非小细胞肺癌的疗效及安全性。方法将60例晚期非小细胞肺癌患者随机分为试验组和对照组各30例，试验组予以紫杉醇酯质体135 mg /m2联合顺铂治疗，对照组予以多西他赛75 mg /m2联合顺铂治疗；2组均以21 d 为1个周期，至少治疗2个周期并评价疗效及毒副反应。结果2组临床疗效比较差异无统计学意义（P ＞0.05）；试验组末梢神经炎发生率低于对照组，差异有统计学意义（P ＜0.05）；2组恶心/呕吐、腹泻、腹痛、脱发等发生率比较差异均无统计学意义（P ＞0.05）。结论紫杉醇酯质体联合顺铂治疗晚期非小细胞肺癌疗效与紫杉醇相当，但末梢神经炎发生率降低，通过各种相应的护理措施，可在达到良好疗效的同时减少毒副反应的发生。